Immune Design (IMDZ) Stock Price, News & Analysis

Company Overview

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.

Key Stats

• Today's Range: $5.85 to $5.85
• 50-Day Range: $5.85 to $5.85
• 52-Week Range: $1.10 to $5.85
• Volume: N/A
• Average Volume: 374,216 shs
• Market Capitalization: $282.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

IMDZ Stock Analysis - Frequently Asked Questions

How were Immune Design's earnings last quarter?

Immune Design Corp. (NASDAQ:IMDZ) issued its earnings results on Wednesday, August, 1st. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.01. The biotechnology company had revenue of $0.76 million for the quarter, compared to analysts' expectations of $0.64 million. Immune Design had a negative net margin of 2,483.00% and a negative trailing twelve-month return on equity of 49.56%.

What other stocks do shareholders of Immune Design own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Immune Design investors own include Omeros (OMER), Progenics Pharmaceuticals (PGNX), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Selecta Biosciences (SELB), TG Therapeutics (TGTX) and TherapeuticsMD (TXMD).

Company Calendar

• Last Earnings: 8/01/2018
• Today: 7/18/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:IMDZ
• CIK: 1437786
• Web: www.immunedesign.com
• Phone: 206-682-0645
• Fax: N/A
• Employees: 48
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($1.75)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$54.76 million
• Net Margins: -2,483.00%
• Pretax Margin: N/A
• Return on Equity: -49.56%
• Return on Assets: -46.21%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.33
• Quick Ratio: 11.32

Sales & Book Value

• Annual Sales: $2.20 million
• Price / Sales: 128.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.91 per share
• Price / Book: 3.06

Miscellaneous

• Outstanding Shares: 48,370,000
• Free Float: N/A
• Market Cap: $282.96 million
• Optionable: Optionable
• Beta: 3.48